Literature DB >> 21180581

Second-line rescue therapy of helicobacter pylori infection.

Javier P Gisbert1.   

Abstract

Helicobacter pylori infection is the main known cause of gastritis, gastroduodenal ulcer disease and gastric cancer. After more than 20 years of experience in H. pylori treatment, however, the ideal regimen to treat this infection has still to be found. Nowadays, apart from having to know well first-line eradication regimens, we must also be prepared to face treatment failures. Therefore, in designing a treatment strategy we should not focus on the results of primary therapy alone, but also on the final (overall) eradication rate. The choice of a 'rescue' treatment depends on which treatment is used initially. If a first-line clarithromycin-based regimen was used, a second-line metronidazole-based treatment (quadruple therapy) may be used afterwards, and then a levofloxacin-based combination would be a third-line 'rescue' option. Alternatively, it has recently been suggested that levofloxacin-based 'rescue' therapy constitutes an encouraging second-line strategy, representing an alternative to quadruple therapy in patients with previous PPI-clarithromycin-amoxicillin failure, with the advantage of efficacy, simplicity and safety. In this case, quadruple regimen may be reserved as a third-line 'rescue' option. Finally, rifabutin-based 'rescue' therapy constitutes an encouraging empirical fourth-line strategy after multiple previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin. Even after two consecutive failures, several studies have demonstrated that H. pylori eradication can finally be achieved in almost all patients if several 'rescue' therapies are consecutively given. Therefore, the attitude in H. pylori eradication therapy failure, even after two or more unsuccessful attempts, should be to fight and not to surrender.

Entities:  

Keywords:  Helicobacter pylori; eradication; levofloxacin; rescue; rifabutin; salvage

Year:  2009        PMID: 21180581      PMCID: PMC3002558          DOI: 10.1177/1756283X09347109

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  207 in total

Review 1.  [Treatment for the eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference].

Authors:  J P Gisbert; X Calvet; F Gomollón; R Sáinz
Journal:  Med Clin (Barc)       Date:  2000-02-12       Impact factor: 1.725

2.  Helicobacter pylori eradication: do we have another ace up our sleeve?

Authors:  A Zullo; C Hassan; R Lorenzetti; S Morini
Journal:  Dig Liver Dis       Date:  2001-12       Impact factor: 4.088

3.  A triple therapy regimen after failed Helicobacter pylori treatments.

Authors:  A Zullo; C Hassan; S M Campo; R Lorenzetti; I Febbraro; M De Matthaeis; D Porto; S Morini
Journal:  Aliment Pharmacol Ther       Date:  2001-08       Impact factor: 8.171

4.  Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection.

Authors:  W M Wong; Q Gu; S K Lam; F M Y Fung; K C Lai; W H C Hu; Y K Yee; C K Chan; H H X Xia; M F Yuen; B C Y Wong
Journal:  Aliment Pharmacol Ther       Date:  2003-02-15       Impact factor: 8.171

5.  High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin.

Authors:  Maribel Rodríguez-Torres; Rosa Salgado-Mercado; Carlos F Ríos-Bedoya; Edgardo Aponte-Rivera; Acisclo M Marxuach-Cuétara; José F Rodríguez-Orengo; Alberto Fernández-Carbia
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

6.  A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.

Authors:  N Magaret; M Burm; D Faigel; C Kelly; W Peterson; M B Fennerty
Journal:  Dig Dis       Date:  2001       Impact factor: 2.404

7.  Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach.

Authors:  M P Dore; G Leandro; G Realdi; A R Sepulveda; D Y Graham
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

8.  High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection.

Authors:  H Isomoto; K Inoue; H Furusu; A Enjoji; C Fujimoto; M Yamakawa; Y Hirakata; K Omagari; Y Mizuta; K Murase; S Shimada; I Murata; S Kohno
Journal:  Aliment Pharmacol Ther       Date:  2003-07-01       Impact factor: 8.171

9.  Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.

Authors:  Engin Altintas; Orhan Sezgin; Oguz Ulu; Ozlem Aydin; Handan Camdeviren
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

10.  Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection.

Authors:  José M Navarro-Jarabo; Nuria Fernández; Francisca L Sousa; Encarnación Cabrera; Manuel Castro; Luz M Ramírez; Robin Rivera; Esther Ubiña; Francisco Vera; Isabel Méndez; Francisco Rivas-Ruiz; José L Moreno; Emilio Perea-Milla
Journal:  BMC Gastroenterol       Date:  2007-07-25       Impact factor: 3.067

View more
  10 in total

1.  Antibiotics resistance rate of Helicobacter pylori in Bhutan.

Authors:  Ratha-korn Vilaichone; Yoshio Yamaoka; Seiji Shiota; Thawee Ratanachu-ek; Lotay Tshering; Tomohisa Uchida; Toshio Fujioka; Varocha Mahachai
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 2.  Helicobacter pylori in First Nations and recent immigrant populations in Canada.

Authors:  Nicola Jones; Naoki Chiba; Carlo Fallone; Alan Thompson; Richard Hunt; Kevan Jacobson; Karen Goodman
Journal:  Can J Gastroenterol       Date:  2012-02       Impact factor: 3.522

3.  Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic.

Authors:  Muhammad Miftahussurur; Modesto Cruz; Phawinee Subsomwong; José A Jiménez Abreu; Celso Hosking; Hiroyuki Nagashima; Junko Akada; Yoshio Yamaoka
Journal:  Am J Trop Med Hyg       Date:  2017-02-13       Impact factor: 2.345

4.  Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans.

Authors:  Seiji Shiota; Rita Reddy; Abeer Alsarraj; Hashem B El-Serag; David Y Graham
Journal:  Clin Gastroenterol Hepatol       Date:  2015-02-11       Impact factor: 11.382

5.  The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam.

Authors:  Tran T Binh; Seiji Shiota; Lam T Nguyen; Dung D Q Ho; Hai H Hoang; Long Ta; Dung T Trinh; Toshio Fujioka; Yoshio Yamaoka
Journal:  J Clin Gastroenterol       Date:  2013-03       Impact factor: 3.062

6.  Helicobacter  pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy.

Authors:  Sotirios D Georgopoulos; Vasilios Papastergiou; Stylianos Karatapanis
Journal:  Gastroenterol Res Pract       Date:  2012-06-19       Impact factor: 2.260

7.  In vitro antagonistic activity of Lactobacillus casei against Helicobacter pylori.

Authors:  Shymaa Enany; Salah Abdalla
Journal:  Braz J Microbiol       Date:  2015-10-27       Impact factor: 2.476

8.  Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea.

Authors:  Ji Yoon Moon; Gwang Ha Kim; Hyun Seok You; Bong Eun Lee; Dong Yeop Ryu; Jae Hoon Cheong; Jung Im Jung; Jae Hoon Jeong; Chul Soo Song; Geun Am Song
Journal:  Gut Liver       Date:  2013-06-11       Impact factor: 4.519

9.  Synthesis and biological evaluation of novel benzyl piperazine derivatives of 5-(5-nitroaryl)-1,3,4-thiadiazoles as Anti-Helicobacter pylori agents.

Authors:  Negar Mohammadhosseini; Parastoo Saniee; Ameneh Ghamaripour; Hassan Aryapour; Farzaneh Afshar; Najmeh Edraki; Farideh Siavoshi; Alireza Foroumadi; Abbas Shafiee
Journal:  Daru       Date:  2013-08-08       Impact factor: 3.117

10.  Sequential Therapy vs Quadruple Therapy for Helicobacter pylori Eradication in South West of Iran.

Authors:  Abdol Rahim Masjedizadeh; Eskandar Hajiani; Seyed Jalal Hashemi; Pezhman Alavinejad; Hasan Dalvand
Journal:  Euroasian J Hepatogastroenterol       Date:  2014-07-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.